
Sharecare announces second quarter 2023 financial results and operational highlights
"Our integrated approach to delivering comprehensive care solutions has proven successful in enhancing user experiences, reducing costs, and measurably improving clinical outcomes across populations, whether people are managing high-risk and chronic conditions or simply require routine preventive care," said
Second Quarter 2023 Financial Results
All comparisons, unless otherwise noted, are to the three months ended
- Revenue of
$110.4 million compared to$103.8 million , an increase of$6.6 million , or 6.3%. - Net loss attributable to
Sharecare of$35.1 million compared to$29.0 million , an increase to net loss attributable toSharecare of$6.1 million . Net loss attributable toSharecare in the second quarter of 2023 included$12.1 million in non-cash stock compensation;$1.4 million in non-operating, non-recurring costs;$8.2 million of reorganizational and severance costs; and$3.8 million of other non-cash or non-operational expense. Excluding these amounts, the adjusted net loss was$9.6 million in the current quarter. - Adjusted EBITDA of
$3.8 million compared to$2.1 million , an increase to adjusted EBITDA of$1.7 million . - Net loss per share of
$0.10 compared to$0.08 , an increase to net loss per share of$0.02 . - Adjusted net loss per share, which excludes the impact of non-cash and non-operational amounts, was
$0.03 compared to$0.02 , an increase to adjusted net loss per share of$0.01 .
Arnold added, “With the conclusion of our strategic review, which we announced in the quarter, the Board came to the unanimous decision that our three business channels – Enterprise, Provider, and Life Sciences – complement one another with a depth and breadth of capabilities that, together, create a unique platform-driven ecosystem built for scale. We are confident that the strategic alignment of these businesses allows us to seize new growth opportunities and serve our expanding customer base and their needs more effectively today and into the future, and we remain committed to maximizing shareholder value.”
“Sharecare’s financial health remains strong, and we are pleased with our performance in the second quarter, expanding adjusted EBITDA margins, substantially improved cash burn, and the robustness of our balance sheet – all of which will help us reach our goal of cash flow breakeven by year's end," said
Financial Outlook
Third Quarter 2023 Financial Guidance
For the three months ending
- Revenue in the range of
$111 million to$113 million - Adjusted EBITDA in the range of
$8 million to$10 million
Fiscal 2023 Financial Guidance
For the twelve months ending
- Revenue in the range of
$452.5 million to$460 million - Adjusted EBITDA in the range of
$25 million to$30 million
Ferrero added, "While our business will continue to have some channel-level seasonality going forward, our expected adjusted EBITDA in the third quarter is indicative of the emerging underlying earnings power of
Conference Call
The Company will host a conference call to review the second quarter results today,
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with
The calculations and reconciliations of historic adjusted EBITDA, adjusted net loss, and adjusted loss per share to net loss, the most directly comparable financial measure stated in accordance with GAAP, are provided below and in the accompanying financial tables. Investors are encouraged to review the reconciliations and not to rely on any single financial measure to evaluate our business.
We have not reconciled adjusted EBITDA guidance to net loss because we do not provide guidance for net loss or for items that we do not consider indicative of our ongoing performance, including, but not limited to, the impact of significant non-recurring items, as certain of these items are out of our control and/or cannot be reasonably predicted. Accordingly, reconciliations of adjusted EBITDA guidance to the corresponding
Adjusted EBITDA
We calculate adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization, (ii) interest income, (iii) interest expense, (iv) income tax expense, (v) other income (expense) (non-operating), (vi) share-based compensation, (vii) warrants issued with revenue contracts, (viii) amortization of non-cash payment for research and development, (ix) net costs associated with exiting a contract, (x) non-operating, non-recurring costs, (xi) reorganizational and severance costs, and (xii) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate the Company’s lines of business and services.
Adjusted Net Loss
We calculate adjusted net loss as net loss attributable to
Adjusted Loss Per Share
We calculate adjusted lost per share as adjusted net loss, as defined above, divided by the number of weighted average common shares outstanding - basic and diluted.
About
Important Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Forward-looking statements in this press release include, but are not limited to, statements regarding our long-term strategy and positioning, growth, globalization and other strategic cost optimization initiatives and the corresponding benefits, including long-term growth, margin improvement and cash flow improvements, and partnerships or other relationships with third parties or customers, in each case on our future growth objectives and statements regarding our future results and outlook, including those under the caption “Financial Outlook.”
We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results. For example, the Company’s Financial Outlook assumes business currently under contract and satisfaction by our customers of their contractual obligations under those agreements, which is not within the Company’s control. If a customer fails to satisfy its contractual obligations, actual revenue and Adjusted EBITDA could be negatively impacted. Descriptions of some of the other factors that could cause actual results to differ materially from these forward-looking statements are discussed in more detail in our filings with the
Media Relations:
jen@sharecare.com
Investor Relations:
SharecareIR@westwicke.com
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Ended |
Six Months Ended |
||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenue (inclusive of revenue for the three months ended 2022, respectively, and party revenue for the six months ended 2022, respectively) |
$ | 110,353 | $ | 103,823 | $ | 226,648 | $ | 204,533 | |||||||
Costs and operating expenses: | |||||||||||||||
Costs of revenue (exclusive of depreciation and amortization; inclusive of costs for three months ended respectively, and the six months ended |
62,948 | 53,238 | 130,840 | 104,730 | |||||||||||
Sales and marketing | 14,959 | 14,155 | 30,309 | 28,666 | |||||||||||
Product and technology | 17,035 | 17,680 | 37,843 | 37,101 | |||||||||||
General and administrative | 35,371 | 43,491 | 69,490 | 99,489 | |||||||||||
Depreciation and amortization | 14,184 | 10,901 | 28,965 | 20,778 | |||||||||||
Total costs and operating expenses | 144,497 | 139,465 | 297,447 | 290,764 | |||||||||||
Loss from operations | (34,144 | ) | (35,642 | ) | (70,799 | ) | (86,231 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest income | 1,646 | 102 | 3,326 | 131 | |||||||||||
Interest expense | (453 | ) | (539 | ) | (882 | ) | (1,031 | ) | |||||||
Other (expense) income | (2,631 | ) | 6,827 | (2,201 | ) | 19,672 | |||||||||
Total other (expense) income | (1,438 | ) | 6,390 | 243 | 18,772 | ||||||||||
Loss before income tax expense | (35,582 | ) | (29,252 | ) | (70,556 | ) | (67,459 | ) | |||||||
Income tax expense | (65 | ) | (269 | ) | (96 | ) | (361 | ) | |||||||
Net loss | (35,647 | ) | (29,521 | ) | (70,652 | ) | (67,820 | ) | |||||||
Net loss attributable to noncontrolling interest in subsidiaries | (504 | ) | (496 | ) | (850 | ) | (594 | ) | |||||||
Net loss attributable to |
$ | (35,143 | ) | $ | (29,025 | ) | $ | (69,802 | ) | $ | (67,226 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.10 | ) | $ | (0.08 | ) | $ | (0.20 | ) | $ | (0.19 | ) | |||
Weighted-average common shares outstanding, basic and diluted | 354,049,808 | 347,334,401 | 353,490,234 | 346,122,333 |
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)
As of 2023 |
As of 2022 |
||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 144,162 | $ | 182,508 | |||
Accounts receivable, net (net of allowance for doubtful accounts of |
123,856 | 116,877 | |||||
Other receivables | 2,329 | 4,114 | |||||
Prepaid expenses | 10,420 | 12,612 | |||||
Other current assets | 4,890 | 4,515 | |||||
Total current assets | 285,657 | 320,626 | |||||
Property and equipment, net | 4,595 | 5,082 | |||||
Other long-term assets | 20,426 | 20,362 | |||||
Intangible assets, net | 152,763 | 163,114 | |||||
191,946 | 191,817 | ||||||
Total assets | $ | 655,387 | $ | 701,001 | |||
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 25,719 | $ | 8,838 | |||
Accrued expenses and other current liabilities | 79,569 | 81,627 | |||||
Deferred revenue | 6,931 | 9,032 | |||||
Contract liabilities, current | 768 | 1,535 | |||||
Total current liabilities | 112,987 | 101,032 | |||||
Warrant liabilities | 3,307 | 2,441 | |||||
Long-term debt | 364 | — | |||||
Other long-term liabilities | 9,565 | 16,723 | |||||
Total liabilities | 126,223 | 120,196 | |||||
Commitments and contingencies | |||||||
Series A convertible redeemable preferred shares, shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of |
58,205 | 58,205 | |||||
Stockholders’ equity: | |||||||
Common stock, authorized; 356,593,964 and 354,463,620 shares issued and outstanding as of |
35 | 35 | |||||
Additional paid-in capital | 1,139,594 | 1,120,024 | |||||
Accumulated other comprehensive loss | (2,370 | ) | (2,794 | ) | |||
Accumulated deficit | (666,677 | ) | (595,820 | ) | |||
Total |
470,582 | 521,445 | |||||
Noncontrolling interest in subsidiaries | 377 | 1,155 | |||||
Total stockholders’ equity | 470,959 | 522,600 | |||||
Total liabilities, redeemable convertible preferred stock and stockholders’ equity | $ | 655,387 | $ | 701,001 |
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(Unaudited)
(In thousands)
Three Months Ended |
Six Months Ended |
||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Net loss | $ | (35,647 | ) | $ | (29,521 | ) | $ | (70,652 | ) | $ | (67,820 | ) | |||
Add: | |||||||||||||||
Depreciation and amortization | 14,184 | 10,901 | 28,965 | 20,778 | |||||||||||
Interest income | (1,646 | ) | (102 | ) | (3,326 | ) | (131 | ) | |||||||
Interest expense | 453 | 539 | 882 | 1,031 | |||||||||||
Income tax expense | 65 | 269 | 96 | 361 | |||||||||||
Other expense (income) | 2,631 | (6,827 | ) | 2,201 | (19,672 | ) | |||||||||
Share-based compensation | 12,149 | 18,177 | 22,116 | 51,287 | |||||||||||
Warrants issued with revenue contracts | 14 | 14 | 28 | 34 | |||||||||||
Amortization of non-cash payment for research and development | 1,190 | 424 | 2,380 | 847 | |||||||||||
Net costs associated with exiting a contract(a) | 505 | 1,249 | 1,222 | 2,923 | |||||||||||
Non-operating, non-recurring costs(b) | 1,427 | 2,281 | 3,142 | 5,037 | |||||||||||
Reorganizational and severance costs(c) | 8,224 | 3,482 | 18,036 | 6,059 | |||||||||||
Acquisition-related costs | 267 | 1,249 | 825 | 3,224 | |||||||||||
Adjusted EBITDA(d) | $ | 3,816 | $ | 2,135 | $ | 5,915 | $ | 3,958 |
(a) | For the three months ended |
(b) | For the three months ended |
(c) | For the three months ended |
(d) | Includes non-cash amortization associated with contract liabilities recorded in connection with acquired businesses. |
RECONCILIATION OF GAAP NET LOSS ATTRIBUTABLE TO SHARECARE TO ADJUSTED NET LOSS AND ADJUSTED LOSS PER SHARE
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended |
Six Months Ended |
||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Net loss attributable to |
$ | (35,143 | ) | $ | (29,025 | ) | $ | (69,802 | ) | $ | (67,226 | ) | |||
Add: | |||||||||||||||
Amortization of acquired intangibles(a) | 1,633 | 1,631 | 3,265 | 3,263 | |||||||||||
Amortization of deferred financing fees | — | 70 | 31 | 138 | |||||||||||
Change in fair value of warrant liability and contingent consideration | 96 | (6,374 | ) | (42 | ) | (18,742 | ) | ||||||||
Share-based compensation | 12,149 | 18,177 | 22,116 | 51,287 | |||||||||||
Warrants issued with revenue contracts | 14 | 14 | 28 | 34 | |||||||||||
Amortization of non-cash payment for research and development | 1,190 | 424 | 2,380 | 847 | |||||||||||
Net costs associated with exiting a contract(b) | 505 | 1,249 | 1,222 | 2,923 | |||||||||||
Non-operating, non-recurring costs(c) | 1,427 | 2,281 | 3,142 | 5,037 | |||||||||||
Reorganizational and severance costs(d) | 8,224 | 3,482 | 18,036 | 6,059 | |||||||||||
Acquisition-related costs | 267 | 1,249 | 825 | 3,224 | |||||||||||
Adjusted net loss(e) | $ | (9,638 | ) | $ | (6,822 | ) | $ | (18,799 | ) | $ | (13,156 | ) | |||
Weighted-average common shares outstanding, basic and diluted | 354,049,808 | 347,334,401 | 353,490,234 | 346,122,333 | |||||||||||
Loss per share | $ | (0.10 | ) | $ | (0.08 | ) | $ | (0.20 | ) | $ | (0.19 | ) | |||
Adjusted loss per share | $ | (0.03 | ) | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.04 | ) |
(a) | Represents non-cash expenses related to the amortization of intangibles in connection with acquired businesses. |
(b) | For the three months ended |
(c) | For the three months ended |
(d) | For the three months ended |
(e) | The income tax effect of the Company’s non-GAAP reconciling items are offset by valuation allowance adjustments of the same amount given the Company is in a full valuation allowance position. |

Source: Sharecare, Inc.